News

Science4Pandemics initiatives to educate young people on pandemic preparedness

09 May, 2023

Science4Pandemics (S4P) is an EU-funded project that aims to educate young people on how to prevent future pandemics through a game-based learning approach. S4P needs your support! S4P is dedicated…
Read More

Join VERDI’s clinical study in paediatric and adolescent mpox

11 Apr, 2023

We would like to invite hospitals to participate in a study of mpox in children and adolescents globally. This mpox paediatric and adolescent clinical study is a Joint EU Clinical Research…
Read More

EU tasks VERDI Consortium with investigating mpox and improving pandemic preparedness

30 Mar, 2023

The VERDI Consortium, coordinated by the University of Padua and Fondazione Penta ETS (Italy), has received an additional €5 million funding from the European Union (EU). Thanks to this contribution,…
Read More

Fondazione Penta changed its name!

30 Mar, 2023

We are pleased to announce that Fondazione Penta has been registered in the Italian Registry of Third Sector Entities (RUNTS). Registration with RUNTS does not entail any legal changes, besides…
Read More

Insights from the NeoIPC webinar on outbreak management in neonatal intensive care units

10 Mar, 2023

On 9 March 2023, the NeoIPC Clinical Practice Network held a webinar titled “Protecting our tiniest patients: Strategies for managing NICU outbreaks”.  The event was a great success, with 78…
Read More

PentaTr@ining: ‘AMR Online Course’ kicks-off! 

20 Feb, 2023

On February 20th 2023, we kicked off our exciting brand-new PentaTr@ining programme ‘AMR Online Course’. This innovative training will offer a bespoke interactive learning platform for a global audience, ensuring the sharing…
Read More

Register for the webinar “Protecting our tiniest patients: Strategies for managing NICU outbreaks”

17 Feb, 2023

Neonatal intensive care units (NICUs) are essential facilities for preterm and sick newborns. Unfortunately, NICUs are also exposed to infectious disease outbreaks that may put these tiny patients at risk. …
Read More

An optimised dosing regimen vs. a standard dosing regimen of vancomycin for the treatment of late onset sepsis due to Gram-positive microorganisms in infants less than 90 days: the NeoVanc trial

14 Feb, 2023

Background: Vancomycin remains one of the most widely prescribed antibiotics for Gram-positive neonatal late onset sep- sis (LOS). Robust neonatal clinical outcome data comparing different vancomycin dosing regimens is lacking.…
Read More

Interim pharmacokinetic analysis of a multi-centre randomised open label phase IIb study in neonates to validate the meta-analysis population pharmacokinetic model used to simulate an optimised dosing regimen in neonates and infants aged < 90 days: the NeoVanc trial

14 Feb, 2023

Background: Vancomycin remains one of the most widely prescribed antibiotics for Gram-positive neonatal late onset sepsis (LOS), however, a consensus on optimal vancomycin dosing and duration is lacking. Robust neonatal…
Read More

MRC Clinical Trials Unit Capacity Strengthening Hub launches!

08 Feb, 2023

We are excited to share that our partner, MRC CTU at UCL, launched the MRC Clinical Trials Unit (MRC CTU) has launched a Capacity Strengthening Hub on 31st January!  The aim of…
Read More

Registrations are open for ‘PentaTr@ining: AMR Online Course’!

03 Feb, 2023

We are happy to announce that registrations are now open* for our new interactive training programme – ‘PentaTr@ining: AMR Online Course’! This timely course brings together doctors, nurses, pharmacists and…
Read More

TEAM-COACH: a new project to train and build capacity in antimicrobial stewardship and infection prevention and control in children

30 Jan, 2023

A new project, Training and capacity building in antimicrobial stewardship and infection prevention and control in children through an interactive electronic tool and a European collaborative group – in short TEAM-COACH (GA 101079939)- has…
Read More

HIPRA’s COVID-19 vaccine trial in people with immunocompromising conditions launches in Turkey

19 Jan, 2023

One of the objectives of the RBDCOV project is to test whether their vaccine can reactivate or re-generate a protective immune response to SARS-CoV-2 in immunocompetent and immunosuppressed individuals Accordingly,…
Read More

Two-thirds recruitment milestone reached for PediCAP!

11 Jan, 2023

We are pleased to have reached the two-thirds recruitment milestone with more than 750 children admitted to hospital with severe or very severe pneumonia, now recruited into the PediCAP trial.…
Read More

Get to know the UNIVERSAL project: Pharmacokinetic study of new DTG/FTC/TAF dose ratio

09 Jan, 2023

Welcome to the of the “Get to know the UNIVERSAL project” series! Here we will introduce you to the various work packages and facets that make up the UNIVERSAL project.…
Read More

2022 End of Year Message from the President of the Penta Foundation, Carlo Giaquinto

30 Dec, 2022

It’s been an incredible year, and Penta is well and thriving. We have worked hard and accomplished so much, none of which would have been possible without our partners, collaborators…
Read More

Get to know the UNIVERSAL project: Assessing the long-term safety of ART drugs

20 Dec, 2022

Welcome to the “Get to know the UNIVERSAL project” series! Here we will introduce you to the various work packages and facets that make up the UNIVERSAL project. Assessing the…
Read More

PentaTr@ining: ‘Fungal Infections in Paediatrics’ online course wraps up! 

20 Dec, 2022

The first ever edition of our brand-new online training course ‘Fungal Infections in Paediatrics’ came to a close on 15th December 2022. We are delighted to report we had an…
Read More
1 2 3 4 5 23